(Q35046895)

6 August 2017

1 reference

title

Fitness of drug resistant HIV-1: methodology and clinical implications (English)

1 reference

6 August 2017

author

Miguel E Quiñones-Mateu

object named as

Miguel E Quiñones-Mateu

series ordinal

1

1 reference

ORCID Public Data File 2021

author name string

Eric J Arts

series ordinal

2

1 reference

6 August 2017

publication date

1 December 2002

1 reference

6 August 2017

published in

Drug Resistance Updates

1 reference

6 August 2017

volume

5

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

224-233

1 reference

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Proposed alternatives for the use of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

HIV drug resistance and viral fitness.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Determinants of virological response to antiretroviral therapy: implications for long-term strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Viruses at the edge of adaptation.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

RNA virus mutations and fitness for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

International perspectives on antiretroviral resistance. Resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Structured treatment interruptions in antiretroviral management of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Implications of antiretroviral resistance on viral fitness

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Memory in viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2802%2900123-1

7 January 2021

10.1016/S1368-7646(02)00123-1

Identifiers

DOI

1 reference

6 August 2017

1 reference